by Dr. C.H. Weaver M.D. 6/2020
Savolitinib may offer advantages over Sutent (sunitinib) for treating papillary renal cell carcinoma (RCC), with MET- cancer driving mutations according to study findings published at the 2020 American Society of Clinical Oncology Annual Meeting.
c-MET receptor tyrosine kinase is a cancer driving mutation that is seen in lung, renal and other cancers, and is associated with a poor prognosis. The precision cancer medicine savolitinib selectively binds to and inhibits the activation of c-Met and disrupts c-Met signal transduction pathways which prevents cell growth inhibition in cancers that overexpress the c-Met protein.
Researchers from Dana-Farber Cancer Institute in Boston, Massachusetts, observed that patients treated with savolitinib, a highly selective MET-directed tyrosine kinase inhibitor, experienced an improvement in survival without cancer to 7 months compared with 5.6 months when compared to Sutent, a standard first line treatment for advanced renal call cancers.
Tisotumab Vedotin – Promising in Advanced Cervical Cancer
Novel precision cancer medicine promising for treatment of advanced ovarian cancer.
Checkpoint Inhibitor Immunotherapy for Treatment of Advanced Cervical Cancer
Checkpoint inhibitor immunotherapy prolongs survival and delays recurrence in advanced cervical cancer.
Precision Antibody-drug conjugate promising in Ovarian Cancer
Learn about the STRO-002 Antibody-drug conjugate in Ovarian Cancer
These results represent a preliminary analyses and further follow up is required. Savolitinib however demonstrated encouraging effectiveness and improved safety over Sutent. Turther investigation of savolitinib as a treatment option for RCC with MET mutations is warranted and ongoing.
- Keep Current with The RCC Newsletter
- Connect With Others in the Cancer Connect RCC Community to Share Information and Support
Choueiri TK, Heng DYC, Lee JL, et al. SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC). Presented at: ASCO20 Virtual Scientific Program. J Clin Oncol. 2020;38(suppl):abstr 5002.